ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2018"

  • Abstract Number: L02 • 2018 ACR/ARHP Annual Meeting

    Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis

    Julie J. Paik1, Jemima Albayda2, Eleni Tiniakou3, Andrew Koenig4 and Lisa Christopher-Stine5, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Pfizer Inc, Collegeville, PA, 5Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy that primarily affects the muscle and skin. In refractory disease, it is common to fail 2 or…
  • Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

    Yusuf Yazici1, Timothy E. McAlindon2, Allan Gibofsky3, Nancy Lane4, Christian Lattermann5, Nebojsa Skrepnik6, Christopher Swearingen1, Anita DiFrancesco1, Jeymi Tambiah1 and Marc Hochberg7, 1Samumed, LLC, San Diego, CA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, 4Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Tucson Orthopaedic Institute, Tucson, AZ, 7University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…
  • Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting

    Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

    Paul Brogan1, Gavin Cleary2, Aimee O. Hersh3, Ozgur Kasapcopur4, Satyapal Rangaraj5, Rae S.M. Yeung6, Andrew Zeft7, Simone Melega8, Paul Brunetta9, Jennifer Cooper10, Pooneh Pordeli11 and Patricia B. Lehane12, 1Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 2Alder Hey Children's Hospital, Liverpool, United Kingdom, 3Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, 4Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, 5Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 6Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 7Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, 8F. Hoffmann-La Roche, Basel, Switzerland, 9Genentech, Inc., South San Francisco, CA, 10Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, 11Hoffmann-La Roche Ltd., Mississauga, ON, Canada, 12Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…
  • Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting

    Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study

    Maya H. Buch1, Bara Erhayiem2, Graham Fent2, Paul Baxter3, Elizabeth M.A. Hensor4, Adam McDiarmid2, Peter Swoboda5, Ananth Kidambi2, David Ripley2, Pankaj Garg2, Sarah Horton4, Raluca Bianca Dumitru4, Kamran Naraghi4, John Greenwood6, Paul Emery7, Sue Pavitt8 and Sven Plein2, 1Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, 2Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, 7University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 8Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom

    Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
  • Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards

    Mark C. Genovese1, Kenneth C. Kalunian2, David Walker3, Jacques-Eric Gottenberg4, Kurt de Vlam5, Neelufar Mozaffarian6, Beatrix Bartok6, Franziska Matzkies6, Jie Gao6, Ying Guo6, Chantal Tasset7, John S. Sundy6 and Tsutomu Takeuchi8, 1Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 3Northumbria Healthcare, United Kingdom, United Kingdom, 4Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 6Gilead Sciences, Inc., Foster City, CA, 7Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology